1. Dallas Wood Dylan griFFin matt Nicholson
HYPERKINESIA
Dallas Wood Dylan griFFin matt Nicholson

2. Current Go-To treatment for PD
Levodopa (L-DOPA)
L-DOPA- a precursor to dopamine
L-DOPA’s size allows it to cross the blood-brain barrier, and enter the Basal Ganglia (where DOPA decarboxylase is and increases dopamine levels)

3. Parkinson’s Disease
Dopaminergic neurons are degenerated, thus an increase in dopamine will reverse the negative effects of PD

4. Co-Treatment L-DOPA + MAO-I
If we inhibit MOA with MOA-I then dopamine concentration will increase
MOA-I inhibits the dopamine regulatory enzyme, monoamine oxidase (MAO)
MAO- deaminates monoamines (ie, dopamine) if levels are too high
Thus, the co-treatment will lead to an overall boost of dopamine

5. Co-Treatment effects
With the long term co-treatment of MAO-I and L-DOPA, patients may develop hyperkinesia
HYPERKINESIA= an increase in muscular activity (excessive/abnormal)

6. Nitric Oxide (NO)
Is a gaseous signaling molecule, known to play a big role in the B.G. to enhance dopamine synthesis
Having too much/too little is bad
Too much= oxidative stress
The Co-treatment is shown to increase NO in the B.G.

7. nNOSI
Can cause dyskinesia symptoms to be reduced